非小细胞肺癌免疫检查点抑制剂假性进展的研究进展OA北大核心CSTPCDMEDLINE

The advent of immune checkpoint inhibitors(ICIs)has greatly improved the prognosis of advanced lung cancer patients,but can lead to pseudoprogression(PsP),which complicates clinical evaluation and management.PsP is manifested as temporary enlargement of the tumour or the appearance of new lesions,etc.,and improvement in imaging occurs with continued treatment,mostly without worsening of clinical symptoms.Currently,there are still difficulties in the early diag-nosis of PsP,and its occurrence mechanism is not yet clear,lacking good predictive factors and related biomarkers.This article reviews the current research status of PsP of ICIs in non-small cell lung cancer in order to provide helpful clinical strategies for oncologists using these drugs.